Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | MERTK | Q12866 | 13/20 | 0.53 |
| ▸ | AXL | P30530 | 8/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256583 | 1.00 | RAB9A (0.55) | RAB9ACYP1A2MERTKAXLTYRO3 | |
| SCHEMBL558768 | 0.82 | MAPK1 (0.48) | MERTKAXLTYRO3FLT3GAS6 | |
| SCHEMBL2259324 | 0.82 | MAPK1 (0.48) | MERTKAXLTYRO3FLT3GAS6 | |
| SCHEMBL2258647 | 0.80 | MAPK10 (0.50) | MERTKAXLTYRO3SMN1; SMN2HTT | |
| SCHEMBL559027 | 0.80 | MAPK10 (0.50) | MERTKAXLTYRO3SMN1; SMN2HTT | |
| SCHEMBL2261729 | 0.79 | MAPK10 (0.52) | RAB9AMERTKAXLTYRO3NPC1 | |
| SCHEMBL559698 | 0.79 | MAPK10 (0.52) | RAB9AMERTKAXLTYRO3NPC1 | |
| SCHEMBL558493 | 0.79 | MAPK10 (0.51) | RAB9AMERTKAXLTYRO3NPC1 | |
| SCHEMBL560142 | 0.79 | TYRO3 (0.54) | MERTKAXLTYRO3FLT3GAS6 | |
| SCHEMBL2256985 | 0.79 | TYRO3 (0.54) | MERTKAXLTYRO3FLT3GAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | RAB9A 1586/4885CYP1A2 467/4885MERTK 2882/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | RAB9A 1586/4885CYP1A2 467/4885MERTK 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.